NCT02670824View on ClinicalTrials.gov

Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

May 31, 2016

Study Completion Date

August 31, 2016

Conditions
Intracerebral Hemorrhage (ICH)
Interventions
DRUG

CN-105

Single and multiple intravenous (IV) doses of CN-105

DRUG

Placebo

Normal Saline

Trial Locations (1)

27705

Duke Clinical Research Institute, Durham

Sponsors

Lead Sponsor

AegisCN LLC
All Listed Sponsors
lead

AegisCN LLC

INDUSTRY

NCT02670824 - Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage | Biotech Hunter | Biotech Hunter